Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T61339
|
||||
| Former ID |
TTDR00001
|
||||
| Target Name |
Alpha-glucosidase
|
||||
| Synonyms |
Alpha-glucosidase
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Cancer [ICD9: 140-229; ICD10: C00-C96] | ||||
| Pompe's disease [ICD10: E74.02] | |||||
| Unspecified [ICD code not available] | |||||
| Target Validation |
T61339
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Deoxynojirimycin | Drug Info | Phase 3 | Pompe's disease | [1] |
| Maltose | Drug Info | Phase 1/2 | Discovery agent | [2] | |
| Inhibitor | 4,6-Dideoxyglucose | Drug Info | [3] | ||
| 6-Deoxy-Alpha-D-Glucose | Drug Info | [3] | |||
| Beta-D-Glucose | Drug Info | [3] | |||
| Deoxynojirimycin | Drug Info | [4] | |||
| Double Oxidized Cysteine | Drug Info | [3] | |||
| Maltose | Drug Info | [5] | |||
| Nicotinamide-Adenine-Dinucleotide | Drug Info | [3] | |||
| Tendamistat | Drug Info | [6] | |||
| Modulator | CS 1036 | Drug Info | |||
| JBP-1 | Drug Info | [7], [8] | |||
| POP-1 | Drug Info | [7], [8] | |||
| References | |||||
| REF 1 | The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat. 2009 Dec;30(12):1683-92. | ||||
| REF 2 | ClinicalTrials.gov (NCT01562626) Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors. U.S. National Institutes of Health. | ||||
| REF 3 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | ||||
| REF 4 | J Med Chem. 1994 Oct 28;37(22):3701-6.Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. | ||||
| REF 5 | DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-4. Nucleic Acids Res. 2011 January | ||||
| REF 6 | Influence of Specific Signal Peptide Mutations on the Expression and Secretion of the alpha -Amylase Inhibitor Tendamistat in Streptomyces lividans. J Biol Chem. 1996 Jun 21;271(25):15244-52. | ||||
| REF 7 | US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. | ||||
| REF 8 | EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.